Table 2.
A. Univariate logistic regression | OR | 95% CI OR | p-value |
---|---|---|---|
Age: >60 vs. ≤60 Y | 4.06 | 1.64–10.05 | 0.002 |
Sex: Male vs. Female | 0.77 | 0.34–1.75 | 0.539 |
Smoking history: Yes vs. No | 0.85 | 0.25–2.88 | 0.792 |
ECOG-PS score: ≥1 vs. 0 | 0.86 | 0.40–1.83 | 0.692 |
Initial EGFR mutation: 19Del vs. L858R | 0.74 | 0.32–1.70 | 0.473 |
Initial EGFR mutation: Others vs. L858R | 0.43 | 0.08–2.21 | 0.314 |
First-line EGFR-TKI: Erlotinib vs. Gefitinib | 0.48 | 0.14–1.64 | 0.245 |
First-line EGFR-TKI: Icotinib vs. Gefitinib | 0.53 | 0.20–1.43 | 0.209 |
First-line EGFR-TKI: Afatinib vs. Gefitinib | 0.91 | 0.08–10.6 | 0.939 |
First-line EGFR-TKI PFS: ≥12 Mo vs. <12 Mo | 1.83 | 0.81–4.14 | 0.148 |
T stage: T3-4 vs. T1-2 | 0.90 | 0.39–2.06 | 0.805 |
N stage: N0-1 vs. N2-3 | 1.17 | 0.48–2.87 | 0.733 |
M stage: M1c vs. M1b | 0.38 | 0.10–1.42 | 0.150 |
Stage: IVb vs. IVa | 0.38 | 0.10–1.42 | 0.150 |
Maximum diameter of BM: >2 cm vs. ≤2 cm | 1.57 | 0.48–5.21 | 0.465 |
Ring enhancement: Yes vs. No | 2.53 | 1.12–5.75 | 0.026 |
Peritumor edema: Yes vs. No | 4.72 | 1.95–11.45 | 0.001 |
Location of BM: Frontal lobe vs. Parietal lobe | 4.67 | 0.89–24.35 | 0.068 |
Location of BM: Occipital lobe vs. Parietal lobe | 2.40 | 0.41–14.11 | 0.333 |
Location of BM: Temporal lobe vs. Parietal lobe | 4.67 | 0.78–28.05 | 0.092 |
Location of BM: Cerebellum vs. Parietal lobe | 0.40 | 0.03–4.96 | 0.476 |
Location of BM: Others vs. Parietal lobe | 2.00 | 0.31–13.06 | 0.469 |
B. Multivariate logistic regression | OR | 95% CI OR | p-value |
---|---|---|---|
Age: >60 vs. ≤60 Y | 4.23 | 1.61–11.25 | 0.003 |
Ring enhancement: Yes vs. No | 2.337 | 0.92–5.94 | 0.074 |
Peritumor edema: Yes vs. No | 3.80 | 1.48–9.77 | 0.006 |
Stepwise regression method, exclusion criteria for variables: p < 0.1.
NSCLC, Non-Small Cell Lung Cancer; ECOG-PS, Eastern Cooperative Oncology Group performance score; EGFR, Epidermal Growth Factor Receptor; TKI, Tyrosine Kinase Inhibitor; PFS, Progression-free survival; BM, brain metastases.